Mobile Health Innovative Solutions v. Apple: Voluntary Dismissal in Health Tech Patent Dispute
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Mobile Health Innovative Solutions, LLC v. Apple, Inc. |
| Fallnummer | 2:24-cv-00014 (Fed. Cir.) |
| Gericht | US-Bezirksgericht für den östlichen Bezirk von Texas |
| Dauer | Jan 2024 – Apr 2024 85 days |
| Ergebnis | Defendant Win — Voluntary Dismissal with Prejudice |
| Streitige Patente | |
| Beschuldigte Produkte | Apple Watch, iPhone, HealthKit, Health App ecosystems |
| Anwalt des Klägers | Randall T. Garteiser of Garteiser Honea PLLC |
| Verteidiger | Mark D. Selwyn and Thomas Sprankling of WilmerHale LLP |
| Richter | Oberrichter Rodney Gilstrap |
Einführung
In a case resolved in just 85 days, Mobile Health Innovative Solutions, LLC voluntarily dismissed its patent infringement lawsuit against Apple, Inc. with prejudice — surrendering all claims without any disclosed settlement, damages award, or adjudication on the merits. Filed January 10, 2024, and closed April 4, 2024, in the U.S. District Court for the Eastern District of Texas, the dispute centered on U.S. Patent No. 11,468,984B2, covering technology related to “establishing a current load level” in health monitoring devices and applications.
The case (No. 2:24-cv-00014) is a textbook example of a short-lived patent assertion that ended quietly but carries notable strategic and procedural lessons for patent attorneys, in-house IP counsel, and R&D professionals operating in the rapidly evolving mobile health technology space. The voluntary dismissal with prejudice — filed under FRCP 41(a)(1)(A)(i) — effectively forecloses any future reassertion of the same claims against Apple, making this outcome consequential despite its speed.
Fallübersicht
Die Parteien
⚖️ Kläger
A patent assertion entity (PAE) focused on mobile health technology IP. As a non-practicing entity (NPE), its principal asset is its patent portfolio, making litigation outcomes directly tied to the viability of its patent claims.
🛡️ Beklagter
A global technology leader whose health monitoring features — embedded in Apple Watch, iPhone, and associated HealthKit and Health app ecosystems — regularly attract patent infringement assertions from NPEs and practicing entities alike. Apple’s IP defense posture is well-established and resource-intensive.
Das streitige Patent
This case involved U.S. Patent No. 11,468,984B2, covering technology related to “establishing a current load level” in health monitoring devices and applications.
- • U.S. Patent No. 11,468,984B2 — Devices, methods, and applications for establishing a current load level (Application No. 16/850,984)
Die beanstandeten Produkte
The complaint targeted Apple products and software involving device-based health monitoring — specifically concerning methods and applications for load-level assessment. Given Apple’s HealthKit architecture and Apple Watch sensor stack, the accused functionality likely intersected with physiological monitoring or health data processing workflows.
Rechtsvertretung
Plaintiff: Randall T. Garteiser of Garteiser Honea PLLC — a boutique Texas firm experienced in NPE patent litigation.
Defendant: A formidable 11-attorney team led by Mark D. Selwyn and Thomas Sprankling of WilmerHale LLP (multiple offices), alongside Gillam & Smith, LLP as local Texas counsel. Apple’s defense team size relative to the case’s rapid closure signals an aggressive early posture.
Developing health tech?
Check if your health tech solution might infringe these or related patents before launch.
Das Urteil und die rechtliche Analyse
Zeitplan des Rechtsstreits und Verfahrensgeschichte
| Meilenstein | Datum |
| Beschwerde eingereicht | 10. Januar 2024 |
| Fall abgeschlossen | April 4, 2024 |
| Gesamtdauer | 85 Tage |
The case was filed in the Eastern District of Texas — historically one of the most plaintiff-friendly patent venues in the United States — before Chief Judge Rodney Gilstrap, one of the nation’s most experienced patent trial judges who presides over a substantial volume of the country’s patent docket annually.
Despite the favorable venue selection, the case closed before any significant procedural milestones: no Markman (claim construction) hearing was scheduled, no summary judgment motions were filed, and no trial date was set. The matter resolved at Docket No. 20 — indicating minimal litigation activity. This compressed timeline strongly suggests that Apple’s early defense posture, likely including pre-answer challenges to the patent’s validity or claim scope, prompted the plaintiff to reassess its litigation position rapidly.
Ergebnis
The Court accepted and acknowledged a voluntary dismissal with prejudice filed by Mobile Health Innovative Solutions, LLC pursuant to FRCP 41(a)(1)(A)(i). The order was unambiguous:
- • All claims and causes of action against Apple are dismissed with prejudice
- • Jede Partei trägt ihre eigenen Kosten, Auslagen und Anwaltshonorare
- • Alle anhängigen Anträge auf Rechtsbehelf werden als gegenstandslos abgelehnt
No damages were awarded. No injunction was issued. No consent judgment or disclosed settlement agreement accompanied the dismissal.
Rechtliche Bedeutung
While non-precedential on substantive patent law, this case is procedurally instructive:
- FRCP 41(a)(1)(A)(i) as a defense tool: Apple’s rapid assembly of an 11-attorney defense team may have signaled overwhelming litigation costs and early invalidity risks to the plaintiff, triggering the voluntary exit.
- NPE litigation economics in EDTX: Even in a historically plaintiff-favorable venue, resource asymmetry can compel early abandonment.
- Prejudicial dismissal consequences: Patent holders asserting through NPE structures must carefully evaluate whether early withdrawal forecloses valuable IP assets against other defendants in the same technology space.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in mobile health technology. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle zugehörigen Patente in diesem Technologiebereich anzeigen
- Sehen Sie, welche Unternehmen am aktivsten im Bereich Gesundheitstechnologie-Patente sind.
- Muster der Anspruchsauslegung verstehen
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Technologie oder Ihr eigenes Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Health data load-level processing
Verwandte Patente
In mobile health tech space
Design-Around-Optionen
Für die meisten Ansprüche verfügbar
✅ Wichtigste Erkenntnisse
FRCP 41(a)(1)(A)(i) dismissals with prejudice permanently bar reassertion against the same defendant — counsel clients on downstream consequences before filing.
Verwandte Rechtsprechung suchen →Venue selection in EDTX does not guarantee plaintiff advantage when defendant resources are asymmetric.
Präzedenzfälle erkunden →The absence of § 285 fee shifting here leaves open questions about whether Apple evaluated pursuing exceptional case designation.
Gebührenentscheidungen verstehen →Monitor patent family members of US11468984B2 for continuation applications that may resurface in future litigation.
Patentfamilien verfolgen →Track NPE assertion patterns in mobile health technology for licensing posture adjustments.
NPE-Trends analysieren →Häufig gestellte Fragen
U.S. Patent No. 11,468,984B2 (Application No. 16/850,984), covering devices, methods, and applications for establishing a current load level in health monitoring contexts.
Plaintiff Mobile Health Innovative Solutions filed a voluntary dismissal under FRCP 41(a)(1)(A)(i). The “with prejudice” designation permanently bars reassertion of the same claims against Apple. No court-adjudicated finding on validity or infringement was issued.
It signals that NPEs asserting health technology patents against well-resourced defendants face significant early economic pressure, potentially limiting assertion strategies and impacting portfolio licensing leverage across the sector.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- PACER — Case No. 2:24-cv-00014, E.D. Tex.
- USPTO Patent Center — U.S. Patent No. 11,468,984B2
- Cornell Legal Information Institute — FRCP 41
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.